About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Latest News about NanoViricides

Recent news which mentions NanoViricides

A New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?
Tickers GILD NNVC PFE
Tags NNVC PFE Biotech
From Benzinga
NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase™ 2024
Tickers NNVC
Tags General NanoViricides Market News
From Benzinga
As 2023 Comes To A Close And Updates Are Expected From Many Companies, Are These Three Unique Biotech Names On Your Watchlist?
Tickers DNA LLY NVO PFE
Tags PFE LLY NVO
From Benzinga
Is This Ticker That InvestorObservers Expects To Soar By More Than 350% Next Year On Your Watchlist?
Tags Partner Content Benzinga Biotech
From Benzinga
NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387
Tags XNYS:NNVC NanoViricides
From TheNewswire.com - RSS (Media)
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
Tickers AZN GSK NNVC PFE
Tags PFE NNVC Biotech
From Benzinga
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
Tickers AZN GSK NNVC PFE
Tags Benzinga Biotech PFE
From Benzinga
First Human Clinical Trials Of A Potentially "Game-Changing Broad Spectrum Antiviral" Are Progressing Successfully – Drug Could Treat COVID, RSV And Many Other Respiratory Viruses
Tickers PFE
Tags General NanoViricides Partner Content
From Benzinga
NanoViricides progressing well with new Covid study
Tags NanoViricides XNYS:NNVC
From TheNewswire.com - RSS (Media)
SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?
Tickers GILD MRK NNVC PFE
Tags Biotech Penny Stocks Benzinga
From Benzinga
NanoViricides testing oral gummy and syrup Covid-19 treatment - Proactive Research Analyst
Tags XNYS:NNVC NanoViricides
From TheNewswire.com - RSS (Media)
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
Tickers GILD MRK NNVC PFE
Tags Market News Partner Content GILD
From Benzinga
NanoViricides take big step forward beginning trials on its antiviral drug NV-CoV-2
Tags NanoViricides XNYS:NNVC
From TheNewswire.com - RSS (Media)
This Biotech's Stock Has Been Under Pressure, Could Upcoming Clinical Trials Of Its Nanotechnology-Based COVID Drug Candidate Be The Start Of An Upward March?
Tickers SGEN SGMO SRPT
Tags SGEN Market News Partner Content
From Benzinga
NanoViricides using unique technology platform to fight against viruses
Tags NanoViricides XNYS:NNVC
From TheNewswire.com - RSS (Media)
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
Tickers AZN GILD MRK MRNA
Tags Benzinga Biotech PFE
From Benzinga
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
Tickers GILD MRK MRNA NVAX
Tags MRNA GILD Market News
From Benzinga
With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It, And To Prepare For Battling Against The Next Lik
Tickers NNVC
Tags NNVC Biotech Benzinga
From Benzinga
This Company Is Looking For A Monkeypox Drug As City Investigates Deaths
Tickers NNVC
Tags Penny Stocks Benzinga Biotech
From Benzinga
European Patent Office Issues Intent To Grant Longeveron Patent Related To Methods To Monitor Efficacy Of Lomecel-B™ Cell Therapy
Tickers LGVN
Tags General NanoViricides Partner Content
From Benzinga
European Patent Office Issues Intent To Grant Longeveron Patent Related To Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy
Tickers LGVN
Tags News Benzinga Biotech
From Benzinga
Omicron BA.4/5 Subvariants Are More Contagious And More Treatment-Resistant, But This Biopharma Reports Working On A Potential Breakthrough
Tickers LLY PFE
Tags Market News Markets Partner Content
From Benzinga
NanoViricides Patents Its Antiviral Nanotechnology for COVID-19, Continuing Its Development of Potentially Broad-Spectrum Drugs That Are Expected To Be Effective Even Against Emerging Variants
Tickers MRNA NNVC PFE
Tags PFE NNVC Biotech
From Benzinga
NanoViricides Begins Drug Development Against Severe Pediatric Hepatitis; Expects To Be Successful In Short Period If Existing Candidates In Drug Library Prove Effective
Tags Benzinga Biotech News
From Benzinga
NanoViricides Reports That It Has Begun Drug Development To Combat Recent Cases Of Severe Pediatric Hepatitis
Tags Press Releases Benzinga Biotech
From Benzinga
Does the FDA Rollback Of Regeneron And Eli Lilly COVID Treatment EUAs Signal A Need To Look Beyond Monoclonal Antibodies? NanoViricides, Inc. Looks To Meet This Need With A New Approach
Tickers GSK LLY NNVC REGN
Tags Market News VIR NanoViricides
From Benzinga
Booster Shots Might Not Be Enough to Beat Omicron, According to Some Nanotech Experts
Tickers BNTX NNVC PFE
Tags Biotech Penny Stocks Benzinga
From Benzinga
NanoViricides Says Data Shows Its New Antiviral Could Fight all COVID-19 Variants
Tickers MRK PFE
Tags PFE Biotech Health Care
From Benzinga
NanoViricides Attempts to Leverage Decades of Combined Pharmaceutical and Biotech Experience To Bring Broad-Spectrum COVID-19 Antiviral to Market
Tickers MRNA NNVC PFE
Tags Biotech Benzinga NNVC
From Benzinga
NanoViricides Says Its Nanomedicine Tech Could Be the Key To Defeating Omicron and Other COVID-19 Variants
Tickers JNJ MRNA NNVC PFE
Tags General NanoViricides MRNA
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.